HRP20191219T1 - Molekule protutijela koje imaju specifičnost za ljudski ox40 - Google Patents
Molekule protutijela koje imaju specifičnost za ljudski ox40 Download PDFInfo
- Publication number
- HRP20191219T1 HRP20191219T1 HRP20191219TT HRP20191219T HRP20191219T1 HR P20191219 T1 HRP20191219 T1 HR P20191219T1 HR P20191219T T HRP20191219T T HR P20191219TT HR P20191219 T HRP20191219 T HR P20191219T HR P20191219 T1 HRP20191219 T1 HR P20191219T1
- Authority
- HR
- Croatia
- Prior art keywords
- fusion protein
- seq
- variable domain
- antibody fusion
- bispecific antibody
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 claims 18
- 102000037865 fusion proteins Human genes 0.000 claims 18
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 3
- 102000008100 Human Serum Albumin Human genes 0.000 claims 3
- 108091006905 Human Serum Albumin Proteins 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 102000050320 human TNFRSF4 Human genes 0.000 claims 3
- 230000001575 pathological effect Effects 0.000 claims 3
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 102000004473 OX40 Ligand Human genes 0.000 claims 2
- 108010042215 OX40 Ligand Proteins 0.000 claims 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 2
- 238000010367 cloning Methods 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 claims 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000031814 IgA Vasculitis Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 206010035737 Pneumonia viral Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000013599 cloning vector Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 208000009421 viral pneumonia Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (19)
1. Fuzijski protein bispecifičnog protutijela koji veže ljudski OX40 i ljudski serumski albumin, te antagonizira vezanje OX40 na OX40L, te fuzijski protein bispecifičnog protutijela obuhvaća:
teški lanac koji sadrži, u slijedu od N-terminalnog kraja, prvu varijabilnu domenu teškog lanca (VH1), CHI domenu i drugu varijabilnu domenu teškog lanca (VH2),
lagani lanac koji sadrži, u slijedu od N-terminalnog kraja, prvu varijabilnu domenu lakog lanca (VL1), CL domenu i drugu varijabilnu domenu laganog lanca (VL2),
pri čemu su navedeni teški i lagani lanci poravnani tako da VH1 i VL1 tvore prvo mjesto vezanja antigena i VH2 i VL2 tvore drugo mjesto vezanja antigena,
pri čemu je antigen vezan za prvo mjesto vezanja antigena ljudski OX40 i antigen vezan za drugo mjesto vezanja antigena je ljudski serumski albumin,
pri čemu prva varijabilna domena teškog lanca (VH1) sadrži sekvencu navedenu u SEQ ID NO:1 za CDR-H1, sekvencu navedenu u SEQ ID NO:2 za CDR-H2 i sekvencu navedenu u SEQ ID NO:3 za CDR-H3 i prva varijabilna domena laganog lanca (VL1) sadrži sekvencu navedenu u SEQ ID NO:4 za CDR-L1, sekvencu navedenu u SEQ ID NO:5 za CDR-L2 i sekvencu navedenu u SEQ ID NO:6 za CDR-L3,
pri čemu druga varijabilna domena teškog lanca (VH2) ima sekvencu navedenu u SEQ ID NO:11 i druga varijabilna domena laganog lanca (VL2) ima sekvencu navedenu u SEQ ID NO: 12 i
druga varijabilna domena teškog lanca (VH2) i druga varijabilna domena laganog lanca (VL2) su povezane disulfidnom vezom.
2. Fuzijski protein bispecifičnog protutijela prema patentnom zahtjevu 1 naznačen time što postoji peptidna poveznica između CHI domene i druge varijabilne domene teškog lanca (VH2).
3. Fuzijski protein bispecifičnog protutijela prema patentnom zahtjevu 1 ili zahtjevu 2 naznačen time što postoji peptidna poveznica između CL domene i druge varijabilne domene laganog lanca (VL2).
4. Fuzijski protein protutijela prema bilo kojem od patentnih zahtjeva 1 do 3 naznačen time što prva varijabilna domena teškog lanca (VH1) sadrži sekvencu navedenu u SEQ ID NO:8.
5. Fuzijski protein protutijela prema bilo kojem od patentnih zahtjeva 1 do 4 naznačen time što prva varijabilna domena lakog lanca (VL1) sadrži sekvencu navedenu u SEQ ID NO:7.
6. Fuzijski protein protutijela prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time što teški lanac sadrži ili se sastoji od sekvence navedene u SEQ ID NO:15.
7. Fuzijski protein protutijela prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time što lagani lanac sadrži ili se sastoji od sekvence navedene u SEQ ID NO:16.
8. Fuzijski protein bispecifičnog protutijela koji veže ljudski OX40 i ljudski serumski albumin, te antagonizira vezanje OX40 do OX40L, naznačen time što fuzijski protein bispecifičnog protutijela ima teški lanac koji sadrži sekvencu navedenu u SEQ ID NO:15 i lagani lanac koji sadrži sekvencu navedenu u SEQ ID NO:16.
9. Izolirana sekvenca DNA naznačena time što kodira fuzijski protein protutijela prema bilo kojem od patentnih zahtjeva 1 do 8.
10. Vektor kloniranja ili ekspresije naznačen time što sadrži jednu ili više DNA sekvenci prema patentnom zahtjevu 9.
11. Vektor prema patentnom zahtjevu 10, naznačen time što vektor sadrži sekvence navedene u SEQ ID NO:22 i SEQ ID NO:24.
12. Stanica domaćin naznačena time što sadrži jedan ili više vektora kloniranja ili ekspresije prema patentnom zahtjevu 10 ili zahtjevu 11.
13. Postupak za proizvodnju fuzijskog proteina protutijela prema bilo kojem od zahtjeva 1 do 8, naznačen time što obuhvaća kultiviranje stanice domaćina prema zahtjevu 12 i izoliranje fuzijskog proteina protutijela.
14. Farmaceutski pripravak naznačen time što sadrži fuzijski protein bispecifičnog protutijela prema bilo kojem od patentnih zahtjeva 1 do 8, u kombinaciji s jednim ili više farmaceutski prihvatljivih pomoćnih sredstava, razrjeđivača ili nosača.
15. Farmaceutski pripravak prema patentnom zahtjevu 14, naznačen time što dodatno sadrži druge aktivne sastojke.
16. Fuzijski protein bispecifičnog protutijela prema bilo kojem od patentnih zahtjeva 1 do 8 ili farmaceutski pripravak prema patentnom zahtjevu 14 ili zahtjevu 15, naznačen time što je za uporabu u terapiji.
17. Fuzijski protein bispecifičnog protutijela prema bilo kojem od patentnih zahtjeva 1 do 8 ili farmaceutski pripravak prema patentnom zahtjevu 14 ili zahtjevu 15, naznačen time što je za uporabu za liječenje ili profilaksu patološkog poremećaja odabranog iz skupine koju čine alergija, KOPB, autoimuna bolest, reumatoidni artritis, astma, bolest presatka protiv domaćina, Crohnova bolest, ulcerativni kolitis, dijabetes tipa 1, multipla skleroza, sistemski eritemski lupus, lupusni nefritis, mijastenija gravis, Gravesova bolest, odbacivanje transplantata, Wegenerova granulomatoza, Henoch-Schonlein purpura, sistemska skleroza i virusna upala pluća.
18. Fuzijski protein bispecifičnog protutijela ili farmaceutski pripravak za uporabu prema patentnom zahtjevu 17, naznačen time što patološki poremećaj je bolest presatka protiv domaćina.
19. Fuzijski protein bispecifičnog protutijela ili farmaceutski pripravak za uporabu prema patentnom zahtjevu 17, naznačen time što patološki poremećaj je sistemski eritemski lupus.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161558545P | 2011-11-11 | 2011-11-11 | |
| PCT/EP2012/072325 WO2013068563A2 (en) | 2011-11-11 | 2012-11-09 | Antibody molecules having specificity for human ox40 |
| EP12803508.6A EP2776469B1 (en) | 2011-11-11 | 2012-11-09 | Antibody molecules having specificity for human ox40 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191219T1 true HRP20191219T1 (hr) | 2019-10-04 |
Family
ID=47388492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191219TT HRP20191219T1 (hr) | 2011-11-11 | 2019-07-05 | Molekule protutijela koje imaju specifičnost za ljudski ox40 |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US9040048B2 (hr) |
| EP (1) | EP2776469B1 (hr) |
| JP (1) | JP6367714B2 (hr) |
| KR (1) | KR102071054B1 (hr) |
| CN (1) | CN103946240B (hr) |
| AP (1) | AP2014007668A0 (hr) |
| AR (1) | AR088820A1 (hr) |
| AU (1) | AU2012333997B2 (hr) |
| BR (1) | BR112014011404A2 (hr) |
| CA (1) | CA2855174C (hr) |
| CL (1) | CL2014001193A1 (hr) |
| CO (1) | CO7010784A2 (hr) |
| CY (1) | CY1122073T1 (hr) |
| DK (1) | DK2776469T3 (hr) |
| EA (1) | EA035112B1 (hr) |
| EC (1) | ECSP14000329A (hr) |
| ES (1) | ES2737998T3 (hr) |
| HR (1) | HRP20191219T1 (hr) |
| HU (1) | HUE044333T2 (hr) |
| IL (1) | IL232420B (hr) |
| LT (1) | LT2776469T (hr) |
| MA (1) | MA35724B1 (hr) |
| MX (1) | MX358391B (hr) |
| MY (1) | MY183795A (hr) |
| PE (1) | PE20141995A1 (hr) |
| PL (1) | PL2776469T3 (hr) |
| PT (1) | PT2776469T (hr) |
| SG (1) | SG11201402093RA (hr) |
| SI (1) | SI2776469T1 (hr) |
| TN (1) | TN2014000206A1 (hr) |
| TR (1) | TR201910721T4 (hr) |
| TW (1) | TWI588155B (hr) |
| UA (1) | UA112203C2 (hr) |
| WO (1) | WO2013068563A2 (hr) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101761929B1 (ko) * | 2009-02-17 | 2017-07-26 | 유씨비 바이오파마 에스피알엘 | 인간 ｏｘ４０에 대한 특이성을 갖는 항체 분자 |
| US20120283415A1 (en) * | 2009-09-10 | 2012-11-08 | Ucb Pharma S.A. | Multivalent Antibodies |
| BR112013004266A8 (pt) | 2010-08-23 | 2018-01-02 | Univ Texas | anticorpos anti-ox40 e métodos de uso dos mesmos. |
| GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| EA032475B1 (ru) * | 2011-09-16 | 2019-06-28 | Юсб Фарма С.А. | Фармацевтическая композиция для снижения продолжительности и/или тяжести диареи, заболеваемости и/или смертности пациента, инфицированного clostridium diffcile или имеющего риск указанного заражения, и ее применение |
| GB201223276D0 (en) | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
| SG11201507781VA (en) | 2013-03-18 | 2015-10-29 | Biocerox Prod Bv | Humanized anti-cd134 (ox40) antibodies and uses thereof |
| WO2015041515A1 (en) | 2013-09-19 | 2015-03-26 | N.V. Nutricia | Improved process for the humanization of animal skim milk |
| AU2015241038A1 (en) | 2014-03-31 | 2016-10-13 | Genentech, Inc. | Combination therapy comprising anti-angiogenesis agents and OX40 binding agonists |
| GB201411320D0 (en) * | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| CN108064169B (zh) | 2015-03-03 | 2022-02-11 | 科马布有限公司 | 抗体、用途和方法 |
| WO2016145085A2 (en) | 2015-03-09 | 2016-09-15 | Celldex Therapeutics, Inc. | Cd27 agonists |
| GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| GB201506868D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method for protein purification |
| GB201506869D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| MX2017014188A (es) | 2015-05-07 | 2018-04-10 | Agenus Inc | Anticuerpos anti-ox40 y metodos para su uso. |
| GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| UA125962C2 (uk) * | 2015-10-02 | 2022-07-20 | Ф. Хоффманн-Ля Рош Аг | Біспецифічна антигензв'язуюча молекула до ox40 та фібробласт-активуючого білка (fap) |
| EP3363816A4 (en) * | 2015-10-15 | 2019-10-09 | Dingfu Biotarget Co., Ltd. | ANTI-OX40 ANTIBODIES AND USES THEREOF |
| SG10201912984WA (en) | 2015-12-02 | 2020-03-30 | Agenus Inc | Antibodies and methods of use thereof |
| GB201521382D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| WO2017096182A1 (en) * | 2015-12-03 | 2017-06-08 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
| GB201521389D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
| IL263834B2 (en) | 2016-06-20 | 2024-01-01 | Kymab Ltd | Antibodies against PD-L1 |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
| KR20210035805A (ko) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 |
| WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
| SG11202112846RA (en) | 2019-08-02 | 2021-12-30 | UCB Biopharma SRL | Methods for purifying antibodies |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| CR20220341A (es) | 2019-12-17 | 2022-08-19 | Amgen Inc | Agonista doble de interleucina-2/receptor de tnf para uso en terapia |
| CN116096906A (zh) | 2020-06-29 | 2023-05-09 | 旗舰创业创新五公司 | 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途 |
| US20220325287A1 (en) | 2021-03-31 | 2022-10-13 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| US20240316104A1 (en) | 2021-06-29 | 2024-09-26 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
| GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
| US5821332A (en) | 1993-11-03 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor on the surface of activated CD4+ T-cells: ACT-4 |
| FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
| GB0124317D0 (en) | 2001-10-10 | 2001-11-28 | Celltech R&D Ltd | Biological products |
| US20040146948A1 (en) | 2002-10-18 | 2004-07-29 | Centenary Institute Of Cancer Medicine And Cell Biology | Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments |
| GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| TWI461436B (zh) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法 |
| EP1966241A2 (en) | 2005-12-05 | 2008-09-10 | Symphogen A/S | Anti-orthopoxvirus recombinant polyclonal antibody |
| WO2007112054A2 (en) | 2006-03-23 | 2007-10-04 | Sea Lane Biotechnologies, Llc | Facilitation of translocation of molecules through the gastrointestinal tract |
| CN101668776A (zh) | 2007-02-27 | 2010-03-10 | 健泰科生物技术公司 | 拮抗剂ox40抗体及其在炎性和自身免疫疾病的治疗中的用途 |
| CN101842387B (zh) | 2007-09-26 | 2014-05-07 | Ucb医药有限公司 | 双特异性抗体融合物 |
| PL2334705T3 (pl) * | 2008-09-26 | 2017-06-30 | Ucb Biopharma Sprl | Produkty biologiczne |
| KR101761929B1 (ko) * | 2009-02-17 | 2017-07-26 | 유씨비 바이오파마 에스피알엘 | 인간 ｏｘ４０에 대한 특이성을 갖는 항체 분자 |
| US20120283415A1 (en) | 2009-09-10 | 2012-11-08 | Ucb Pharma S.A. | Multivalent Antibodies |
| GB201005063D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
| JP5522668B2 (ja) | 2010-02-03 | 2014-06-18 | 株式会社ブリヂストン | タイヤ構成部材の切断装置及び製造方法 |
| PT2776466T (pt) * | 2011-11-11 | 2017-11-30 | Ucb Biopharma Sprl | Anticorpos de ligação a albumina e seus fragmentos de ligação |
-
2012
- 2012-09-11 UA UAA201404941A patent/UA112203C2/uk unknown
- 2012-11-08 US US13/672,077 patent/US9040048B2/en not_active Expired - Fee Related
- 2012-11-09 MX MX2014005564A patent/MX358391B/es active IP Right Grant
- 2012-11-09 MY MYPI2014701189A patent/MY183795A/en unknown
- 2012-11-09 TW TW101141760A patent/TWI588155B/zh not_active IP Right Cessation
- 2012-11-09 KR KR1020147015520A patent/KR102071054B1/ko active IP Right Grant
- 2012-11-09 DK DK12803508.6T patent/DK2776469T3/da active
- 2012-11-09 CN CN201280055398.8A patent/CN103946240B/zh not_active Expired - Fee Related
- 2012-11-09 EA EA201400565A patent/EA035112B1/ru not_active IP Right Cessation
- 2012-11-09 PT PT12803508T patent/PT2776469T/pt unknown
- 2012-11-09 AP AP2014007668A patent/AP2014007668A0/xx unknown
- 2012-11-09 WO PCT/EP2012/072325 patent/WO2013068563A2/en active Application Filing
- 2012-11-09 ES ES12803508T patent/ES2737998T3/es active Active
- 2012-11-09 EP EP12803508.6A patent/EP2776469B1/en active Active
- 2012-11-09 SG SG11201402093RA patent/SG11201402093RA/en unknown
- 2012-11-09 JP JP2014540489A patent/JP6367714B2/ja not_active Expired - Fee Related
- 2012-11-09 CA CA2855174A patent/CA2855174C/en not_active Expired - Fee Related
- 2012-11-09 SI SI201231633T patent/SI2776469T1/sl unknown
- 2012-11-09 AU AU2012333997A patent/AU2012333997B2/en not_active Ceased
- 2012-11-09 PL PL12803508T patent/PL2776469T3/pl unknown
- 2012-11-09 BR BR112014011404A patent/BR112014011404A2/pt not_active Application Discontinuation
- 2012-11-09 HU HUE12803508 patent/HUE044333T2/hu unknown
- 2012-11-09 TR TR2019/10721T patent/TR201910721T4/tr unknown
- 2012-11-09 AR ARP120104230A patent/AR088820A1/es unknown
- 2012-11-09 LT LTEP12803508.6T patent/LT2776469T/lt unknown
- 2012-11-09 PE PE2014000673A patent/PE20141995A1/es active IP Right Grant
-
2014
- 2014-05-01 IL IL232420A patent/IL232420B/en active IP Right Grant
- 2014-05-07 CL CL2014001193A patent/CL2014001193A1/es unknown
- 2014-05-08 TN TNP2014000206A patent/TN2014000206A1/en unknown
- 2014-05-08 CO CO14099147A patent/CO7010784A2/es unknown
- 2014-05-08 EC ECIEPI2014329A patent/ECSP14000329A/es unknown
- 2014-06-05 MA MA37104A patent/MA35724B1/fr unknown
-
2015
- 2015-04-27 US US14/697,142 patent/US9873735B2/en active Active
-
2019
- 2019-07-05 HR HRP20191219TT patent/HRP20191219T1/hr unknown
- 2019-07-23 CY CY20191100781T patent/CY1122073T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191219T1 (hr) | Molekule protutijela koje imaju specifičnost za ljudski ox40 | |
| HRP20210739T1 (hr) | Molekule koje vežu antigen i sadrže trimer obitelji tnf liganada | |
| WO2021244089A1 (zh) | 新型冠状病毒（sars-cov-2）刺突蛋白结合分子及其应用 | |
| WO2017133640A1 (en) | Broadly neutralizing antibodies against hiv-1 and use thereof | |
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| RU2577228C2 (ru) | Анти-il-17-антитела, способ их получения и способ применения | |
| HRP20191697T1 (hr) | Vezujuće molekule za bcma i cd3 | |
| WO2017133639A1 (en) | Broadly neutralizing antibodies against hiv-1 and use thereof | |
| JP2012501670A5 (hr) | ||
| RU2609627C2 (ru) | Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh | |
| WO2017106383A4 (en) | Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof | |
| JP2012525829A5 (hr) | ||
| JP2018537421A5 (hr) | ||
| JP2018521638A5 (hr) | ||
| IL295295A (en) | Antibodies against fcrl5 and methods of their use | |
| RU2012107286A (ru) | Высокоаффинные человеческие антитела к человеческому ангиопоэтину-2 | |
| RU2012147286A (ru) | Гуманизированные антитела к фактору d и их применения | |
| JP2016536322A5 (hr) | ||
| RU2018112861A (ru) | Стабильные антитела, связывающиеся с несколькими антигенами | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| US9556254B2 (en) | Cross-reactive antibodies against dengue virus and uses thereof | |
| JP2010502183A5 (hr) | ||
| JP2012518425A5 (hr) | ||
| JP2016519124A5 (hr) | ||
| JP2012524071A5 (hr) |